Anne Lazareth

Pierre-la-treiche, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances
Published: June 30, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances
Published: June 30, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances
Published: June 30, 2025

Teclistamab for relapsed refractory multiple myeloma patients on dialysis.

Teclistamab for relapsed refractory multiple myeloma patients on dialysis.

Journal: British journal of haematology
Published: July 15, 2024

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.

Journal: Hematological oncology
Published: July 11, 2024

End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.

End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.

Journal: Frontiers in oncology
Published: May 22, 2024

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.

Journal: British journal of haematology
Published: March 17, 2024

Sudden-onset painful eruption of the hands: A cutaneous chimeric antigen receptor T-cell therapy reaction.

Sudden-onset painful eruption of the hands: A cutaneous chimeric antigen receptor T-cell therapy reaction.

Journal: JAAD case reports
Published: September 29, 2023

Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas.

Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas.

Journal: Leukemia & lymphoma
Published: December 27, 2022

Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.

Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.

Journal: Leukemia & lymphoma
Published: November 01, 2021

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma.

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma.

Journal: Blood advances
Published: August 11, 2021

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.

Journal: Clinical nuclear medicine
Published: June 11, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026